Serum soluble urokinase-type plasminogen activator receptor and interferon-γ-induced protein 10 levels correlate with significant fibrosis in chronic hepatitis B

Sevgi, Dilek Yıldız; Bayraktar, Banu; Gündüz, Alper; Özgüven, Banu Yılmaz; Togay, Alper; Bulut, Emin; Uzun, Nuray; Dökmetaş, İlyas

doi:10.1007/s00508-015-0886-4

Cited by 23 publications

(17 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IP-10 has recently been shown to be a useful biomarker for identifying patients with significant fibrosis (Sevgi et al, 2016), and IP-10 levels are associated with a decrease in ALT levels (Yoshio et al, 2016). In this study, we first measured IP-10 levels in different patient groups using peripheral blood collected before and after antiviral therapy.…”

Section: Discussionmentioning

confidence: 99%

IP-10 Expression in Patients with Chronic HBV Infection and Its Ability to Predict the Decrease in HBsAg Levels after Treatment with Entecavir

Zhao

Yang

Sun

et al. 2017

Molecules and Cells

View full text Add to dashboard Cite

Interferon-γ-inducible protein 10 (IP-10), also known as chemokine C-X-C motif ligand (CXCL) 10, is closely associated with antiviral immunity and the progression of chronic hepatitis B (CHB). However, the value of baseline serological and histological IP-10 expression levels in predicting the efficacy of the antiviral response to nucleoside/nucleotide analogues (NAs) is still unknown. In our research, intrahepatic and peripheral IP-10 expression levels were systemically examined before and after treatment with entecavir (ETV). Baseline serological and histological IP-10 expression levels were significantly increased in patients with CHB, particularly in patients with higher degrees of liver inflammation and liver fibrosis. Moreover, higher baseline intrahepatic IP-10 levels indicated better prognoses in patients with CHB after entecavir therapy. The baseline IP-10 level was also positively associated with several clinical parameters, including baseline levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), hepatitis B virus (HBV) DNA, and hepatitis B surface antigen (HBsAg), and with the decrease in HBsAg levels after treatment. In addition, monocyte-derived IP-10 was expressed at higher levels in patients with CHB than in patients with liver cirrhosis (LC) and healthy controls (HC). According to the results of our in vitro experiments, IP-10 directly promoted hepatocyte apoptosis. Based on these findings, baseline serological and histological IP-10 levels might predict CHB severity and the decrease in HBsAg levels after entecavir therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

IP-10 Expression in Patients with Chronic HBV Infection and Its Ability to Predict the Decrease in HBsAg Levels after Treatment with Entecavir

Zhao

Yang

Sun

et al. 2017

Molecules and Cells

View full text Add to dashboard Cite

show abstract

“…Without surgery, children with biliary atresia will finally die due to biliary cirrhosis and liver failure[1]. Recently, circulating uPAR levels have been shown to be involved in chronic liver disorders, including chronic hepatitis B and C, liver cirrhosis, and hepatocellular carcinoma[17-20]. Based on our experience, there is no report about circulating uPAR and hepatic fibrosis in various degrees of postoperative biliary atresia.…”

Section: Discussionmentioning

confidence: 99%

Elevation of serum urokinase plasminogen activator receptor and liver stiffness in postoperative biliary atresia

Udomsinprasert

Honsawek

Jirathanathornnukul

et al. 2016

WJH

View full text Add to dashboard Cite

AIMTo investigate serum urokinase-type plasminogen activator receptor (uPAR) and liver stiffness in biliary atresia (BA) and examine the correlation of circulating uPAR, liver stiffness, and clinical outcomes in postoperative BA children.METHODSEighty-five postKasai BA children and 24 control subjects were registered. Circulating uPAR was measured using enzyme-linked immunosorbent essay. Liver stiffness was analyzed using transient elastography.RESULTSBA children had significantly greater circulating uPAR and liver stiffness scores than control subjects (P < 0.001). Circulating uPAR and liver stiffness were substantially higher in jaundiced BA children than non-jaundiced BA children (P < 0.001). In addition, circulating uPAR was positively associated with serum aspartate aminotransferase (r = 0.507, P < 0.001), alanine aminotransferase (r = 0.364, P < 0.001), total bilirubin (r = 0.559, P < 0.001), alkaline phosphatase (r = 0.325, P < 0.001), and liver stiffness scores (r = 0.508, P < 0.001).CONCLUSIONCirculating uPAR and liver stiffness values were greater in BA children than healthy controls. The increased circulating uPAR was associated with liver dysfunction in BA. As a consequence, serum uPAR and liver stiffness may be used as noninvasive biomarkers indicating the progression of liver fibrosis in postKasai BA.

show abstract

“…liver fibrosis), where elevated levels of IP-10 were detected. 37 Antonelli and colleagues demonstrated that high IP-10 values are associated with more severe clinical phenotype and with the presence of lung fibrosis in systemic sclerosis patients. 38 Markers of inflammatory activity are important for the assessment and management of chronic airway diseases with chronic inflammation and loss of lung volume, like chronic obstructive pulmonary disease (COPD).…”

Section: 13mentioning

confidence: 99%

CCL21 and IP-10 as blood biomarkers for pulmonary involvement in systemic lupus erythematosus patients

Odler

Bikov

Streizig

et al. 2016

Lupus

View full text Add to dashboard Cite

Biomarkers for pulmonary manifestations in systemic lupus erythematosus (SLE) are missing. Plasma samples of nine SLE patients with known pulmonary involvement (SLE pulm ) and nine SLE patients without pulmonary involvement (SLE) were tested by multiplex microarray analysis for various cyto-and chemokines. Significantly decreased lung function paramters for forced vital capacity (FVC), total lung capacity (TLC), diffusion capacity for carbon monoxide (DL CO ) and diffusion of CO corrected on lung volume (KL CO ) were observed in SLE pulm as compared to SLE patients. CC chemokine ligand 21 (CCL21) and interferon gamma-induced protein 10 (IP-10) levels were significantly higher in SLE pulm , than in patients without pulmonary manifestations. CCL21 correlated negatively with DL CO (r ¼ À0.73; p < 0.01) and KL CO (r ¼ À0.62; p < 0.01), while IP-10 with FVC and forced expiratory volume one second. Receiver Operating Characteristics (ROC) analysis confirmed high sensitivity and specificity for the separation of SLE patients with and without pulmonary involvement for the chemokines CCL21 (Area Under Curve (AUC): 0.85; sensitivity%: 88.90; specificity%: 75.00; p < 0.01) and IP-10 (AUC: 0.82; sensitivity%: 66.67, specificity%: 100; p < 0.01). Pleuropulmonary manifestations in SLE patients associated with lung functional and DL CO /KL CO changes and were associated with significant increase in CCL21 and IP-10. These chemokines might serve as potential biomarkers of lung involvement in SLE patients. Lupus (2016) 0, 1-8.

show abstract

Serum soluble urokinase-type plasminogen activator receptor and interferon-γ-induced protein 10 levels correlate with significant fibrosis in chronic hepatitis B

Abstract: suPAR and IP-10 were able to distinguish between significant and mild fibrosis with good sensitivity and specificity, and may thus represent useful biomarkers for identifying patients with significant fibrosis.

Cited by 23 publications

References 25 publications

IP-10 Expression in Patients with Chronic HBV Infection and Its Ability to Predict the Decrease in HBsAg Levels after Treatment with Entecavir

IP-10 Expression in Patients with Chronic HBV Infection and Its Ability to Predict the Decrease in HBsAg Levels after Treatment with Entecavir

Elevation of serum urokinase plasminogen activator receptor and liver stiffness in postoperative biliary atresia

CCL21 and IP-10 as blood biomarkers for pulmonary involvement in systemic lupus erythematosus patients

Contact Info

Product

Resources

About